NASDAQ: LHDX

Lucira Health, Inc.

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Lucira Health, Inc. (NASDAQ: LHDX) resulting from allegations that Lucira may have issued materially misleading business information to the investing public.

If you purchased Lucira securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased Lucira securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Details of investigation:

On October 8, 2021, pre-market, Lucira issued a press release reporting that its supply partner Copan Italia SPA announced a recall of its FLOQSwabs included in the LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit. The press release stated that “[a]ccording to Lucira’s records, Test Kits containing the recalled Copan swabs were distributed from April 22, 2021 through September 22, 2021,” and that the recalled Copan swabs should not be used and should be disposed.

On this news, Lucira’s stock price dropped sharply during intraday trading on October 8, 2021, damaging investors.

关注我们:
公司名称: Lucira Health, Inc.
股票代号: LHDX
集体诉讼期: N/A
法院: N/A

为何选择罗森律师事务所?

自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。

投资者应仔细鉴别和遴选在引领证券集体诉讼方面有多年成功经验的的律师。通常,其他律所会发布关于集体诉讼的新闻稿,但却没有类似的经验或资源。

机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。

罗森律师事务所为全球投资者提供代理服务。我们的使命是提起证券欺诈集体诉讼以及保护股东的权利。

滚动至顶部